Successful Exit Lunaphore
The company announced that it has entered into an agreement to be acquired by Bio-Techne Corporation (NASDAQ: TECH), a global life sciences company.
News
Thermosome receives important grant
Thermosome receives a € 1.3 million grant from the Innovative Health Initiative and becomes part of IMAGIO consortium.
Positive Interim Analysis
Good news and great hope for all patients suffering from chronic neuropathic pain comes from our portfolio company Algiax Pharmaceuticals.
First Patient In
The Munich-based drug development company Thermosome, specialized in targeted tumor therapies, announced that the first patient has been dosed.
Tubulis to collaborate with Bristol Myers Squibb
Tubulis hase announced a strategic license agreement to develop the next generation of ultra-stable antibody-drug conjugates (ADCs) for the treatment of solid tumors.
Strategic Partnership of Bio-Techne and Lunaphore
Bio-Techne and our portfolio company Lunaphore have partnered to develop a fully automated spatial multiomics workflow for the detection of protein and RNA biomarkers on the same slide.
Resistell collaborates with CRISP
New collaboration with the Center for Research and Innovation in Clinical Pharmaceutical Sciences (CRISP) at the University Hosptial of Lausanne (CHUV).
InSphero announces financing round with ZEISS Ventures
InSphero is the global market leader in 3D spheroids and cell-based assays for pharmaceutical drug discovery and safety testing.
adivo starts clinical study
The Munich based biotech startup announced its first development project entering first-in-patient clinical studies.